(BPT) - Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness in one or more muscles. Spasticity is usually caused by damage to nerve pathways in the brain or ...

The FDA has approved Botox for the treatment of lower limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy. The treatment was already approved for ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen) today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of Dysport ® ...

“Adult patients who have developed spasticity as a result of a stroke, multiple sclerosis, cerebral palsy, spinal cord injury, or traumatic brain injury now have another option when seeking treatment ...

The US Food and Drug Administration (FDA) has approved onabotulinumtoxinA (Botox, Allergan) to ease lower-limb spasticity in children and adolescents aged 2 years to 17 years, excluding spasticity ...

DUBLIN, Jan. 22, 2016 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® ...

BURLINGTON, Ontario, December 17, 2024--(BUSINESS WIRE)--Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN ® ...

The US Food and Drug Administration (FDA) has approved abobotulinumtoxinA (Dysport, Ipsen Biopharmaceuticals Inc) injection for treatment of lower-limb spasticity in children as young 2 years. Dysport ...

With this approval, DYSPORT THERAPEUTIC now has the broadest label of all approved botulinum neurotoxins for spasticity, which includes both upper and lower limb spasticity in adults, as well as lower ...

- BOTOX® is the First and Only FDA-Approved Neurotoxin Treatment for Both Upper and Lower Limb Spasticity - DUBLIN, Jan. 22, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global ...